All the news Showing 10 of 87 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources HIV-positive people with fatty liver disease are at high risk for fibrosis Liz Highleyman / 23 March 2020 People living with HIV who have non-alcoholic fatty liver disease (NAFLD) often have liver fibrosis and are at risk for fibrosis worsening, researchers reported earlier this month at the Conference ... 'Another swing, another miss' for Gilead as NASH combo flops in phase 2 Fierce Biotech / 16 December 2019 Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) Gilead press release / 16 December 2019 Global burden of deaths and liver cancer due to non-alcoholic fatty liver disease growing Keith Alcorn / 11 December 2019 Non-alcoholic fatty liver disease is a growing cause of liver cancer and death in some regions of the world, an analysis of global reporting on liver disease shows. The findings ... New NASH therapies show promise in mid-stage studies Liz Highleyman / 26 November 2019 Phase II study results presented at the AASLD Liver Meeting this month in Boston show that a number of experimental therapies improve markers of liver health in people with non-alcoholic steatohepatitis (NASH). ... People with fatty liver disease struggle to lose weight Liz Highleyman / 25 November 2019 Losing weight may be especially difficult for people with fatty liver disease due to differences in their metabolism. But nonetheless, some can succeed and doing so improves liver health, according to studies ... Emricasan and selonsertib fail to improve fibrosis in people with NASH Liz Highleyman / 12 November 2019 A pair of experimental therapies for non-alcoholic steatohepatitis (NASH) failed to offer notable improvements in controlled clinical trials, despite having shown promising effects on liver biomarkers in earlier studies. Dr Stephen Harrison ... Fatty livers halt tumor-suppressing protein, increasing cancer risk Fierce Biotech / 21 October 2019 Tesamorelin reduces liver fat and fibrosis progression in people with HIV and NAFLD Keith Alcorn / 21 October 2019 Treatment with tesamorelin, a synthetic growth hormone-releasing hormone, reduced liver fat content and reduced the progression of liver fibrosis in people with HIV who had non-alcoholic fatty liver disease (NAFLD), researchers report ... Obesity epidemic results in Non-Alcoholic Fatty Liver Disease (NAFLD) becoming the most common cause of liver disease in Europe EASL / 26 September 2019 ← Prev1...23456...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive